je.st
news
Tag: orphan
MabVax Therapeutics Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma
2014-10-01 14:02:11| drugdiscoveryonline Home Page
MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma
Tags: drug
cancer
treat
receives
FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin
2014-09-29 15:24:53| Biotech - Topix.net
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme , small cell lung cancer and ovarian cancer . Aldoxorubicin is CytRx's modified version of the widely-used chemotherapeutic agent, doxorubicin.
Tags: multiple
drug
grants
fda
Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies
2014-09-03 12:18:47| drugdiscoveryonline Home Page
Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, recently announced that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, specifically apoA-I deficiency and ABCA1 deficiency
Tags: treatment
drug
receives
deficiencies
Regulus Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome
2014-07-30 10:28:24| drugdiscoveryonline Home Page
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"), as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy
Tags: of
treatment
drug
receives
Nuvilex CEO And COO Discuss Preclinical And Clinical Trials, Orphan...
2014-06-05 09:53:20| Logistics - Topix.net
Nuvilex, Inc. President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's pancreatic cancer treatment in an interview with Stock Market Media Group, a research and content development investment relations firm, while the two were attending the American Society of Clinical Oncology ... (more)
Tags: discuss
clinical
ceo
trials